Partnership Development Manager

Causaly brings agentic scientific research into Microsoft (NASDAQ: MSFT) Copilot for biopharma enterprises. Causaly has announced an expansion of its collaboration with Microsoft (NASDAQ: MSFT) that integrates agentic scientific research capabilities directly into Microsoft Copilot for enterprise life sciences teams. Enterprise scientists and knowledge workers can now access Causaly's scientifically grounded research from within Microsoft 365 workflows, including the Copilot app and Microsoft Teams. The integration allows Causaly to act as a specialized enterprise agent, orchestrating end-to-end scientific research that surfaces prior science and reasons over biological mechanisms. Users can invoke Causaly from the agent menu or by @mentioning Causaly in a Copilot conversation, enabling complex biomedical questions to be answered within a familiar interface. Every answer produced by Causaly carries traceable references back to peer-reviewed literature, biomedical databases, and its proprietary knowledge graphs, Bio Graph and Pipeline Graph. The announcement builds on a collaboration first unveiled at Microsoft Build 2026 in June, which brought Causaly's scientific interpretation together with Microsoft Discovery's enterprise scientific platform. Yiannis Kiachopoulos, co-founder and CEO of Causaly, said: "This puts governed, provenance-first scientific reasoning inside the same interface used across research, development, medical, and commercial functions in biopharma." Kiachopoulos added: "In June we announced the deployment of Causaly's Agentic Research on Microsoft Discovery. Today we are extending that collaboration to Microsoft Copilot, the productivity surface where enterprise knowledge workers already do their day-to-day work." Chantrelle Neilsen, principal product manager for Microsoft 365 Copilot at Microsoft, described the integration as a model for what specialized enterprise agents should look like inside Copilot. Neilsen said: "Grounded in evidence, accountable to the domain, and available where the work happens," characterizing the Causaly integration as making AI more useful without requiring users to switch between tools. For biopharma customers, the combined effect is evidence-grounded scientific reasoning available across Microsoft surfaces their teams already rely on for daily productivity tasks. Causaly, which describes itself as an agentic AI platform purpose-built for life sciences research and development, says leading pharmaceutical and biotechnology organizations use its platform to accelerate drug discovery. Causaly is currently available on the Microsoft Marketplace, with the integration designed to support evidence-grounded research workflows across both Microsoft Discovery and Microsoft Copilot.

Syneos Health advances ai-powered clinical ecosystem to optimize trial performance and speed decision-making. Expanding set of partners and proprietary insights strengthens operational performance. MORRISVILLE, N.C., Aug. 18, 2026 (GLOBE NEWSWIRE) - Syneos Health(R), a leading fully integrated biopharmaceutical solutions organization, today announced the continued advancement of its AI ecosystem - a unified, enterprise approach that embeds artificial intelligence (AI) directly into the core of clinical development. By combining deep therapeutic expertise, healthcare professional intelligence and modern AI technologies, Syneos Health is helping sponsors navigate an increasingly complex development landscape. Grounded in decades of clinical and commercial experience, Syneos Health's differentiated AI approach focuses on integrating advanced capabilities into critical decision points across protocol design, feasibility, enrollment planning, site activation, monitoring and operational oversight. This enables teams to anticipate risk earlier, reduce friction across workflows and make faster, more informed decisions that improve study performance. "Our priority is AI that works inside the complexity of clinical trials. By combining advanced AI with a deep understanding of sites, physicians, patients and the operational dynamics that shape trial performance, we're unlocking new opportunities for speed, clarity and quality," said Mike Montello, Chief Digital and Information Officer, Syneos Health. "When technology is applied precisely at critical decision points, teams can anticipate risk earlier to accelerate development." Enterprise AI and Data Platforms Syneos Health is building a future ready ecosystem bringing together capabilities combining scientific expertise, connected data and evidence, and AI-enabled execution. This integrated approach creates a unified intelligence environment that enables faster, more informed decisions across the clinical development lifecycle. * Causaly - Syneos Health's new collaboration with Causaly applies agentic, evidence-based scientific reasoning to enable faster protocol strategy development, feasibility planning and competitive trial intelligence. Built specifically for the life sciences sector, Causaly's Agentic Research surfaces evidence from a proprietary knowledge graph combining biomedical research and commercial insights. By accelerating analysis of complex biomedical literature and emerging data, Syneos Health teams have reduced the time it takes to derive insights for study strategy and design by approximately 50%. * Databricks - Using Databricks enables Syneos Health to create a more powerful, unified intelligence environment that brings together operational, clinical and real-world data to advance modern clinical development. Leveraging the Databricks Data + AI Platform, Syneos Health has developed a continuous, near real-time view of clinical operations that reduces the time from source data capture to review-ready insight from days to hours, enabling faster intervention and more efficient trial execution. * Microsoft - Building on its long-standing collaboration that began in 2023, Syneos Health is driving AI adoption through its integration with Microsoft. Specifically, Syneos Health has used Microsoft Power Apps and other tools to develop more than 280 agents that integrate with Microsoft 365 Copilot to improve productivity, streamline workflows and support faster, more confident decision-making across the company. Complementing these foundational capabilities are frontier agentic AI solutions and proprietary Syneos Health insights embedded directly within clinical workflows. Together, they help improve predictability, reduce operational complexity, and drive more precise, scalable trial performance. These capabilities are deployed with strong human oversight and governance, ensuring responsible use in regulated environments. "What differentiates Syneos Health is our ability to redesign how clinical development decisions are made through the combination of scientific intelligence, connected evidence, operational expertise and AI-enabled execution across the development lifecycle," said Michael Brooks, Chief Operating Officer, Syneos Health. "By grounding AI in deep clinical expertise and real-world experience, we help sponsors reduce complexity, make better-informed decisions and ultimately deliver better outcomes for patients." About Syneos Health Syneos Health(R) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. News Break Middle East translate unique clinical, commercial and real world insights into outcomes to address modern market realities. News Break Middle East bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together News Break Middle East share diverse insights, use the latest technologies and apply advanced business practices to speed its customers' delivery of important therapies to patients. Syneos Health is powered by an authentic, inclusive and high-performance culture that cares for colleagues, customers, patients, communities and the environment. Press/Media Contact: Meg Byers Director, External Communications [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. News Break Middle East do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.